CA2864483A1 - Aminopyrazine derivatives useful for the treatment or prevention of malaria - Google Patents
Aminopyrazine derivatives useful for the treatment or prevention of malaria Download PDFInfo
- Publication number
- CA2864483A1 CA2864483A1 CA2864483A CA2864483A CA2864483A1 CA 2864483 A1 CA2864483 A1 CA 2864483A1 CA 2864483 A CA2864483 A CA 2864483A CA 2864483 A CA2864483 A CA 2864483A CA 2864483 A1 CA2864483 A1 CA 2864483A1
- Authority
- CA
- Canada
- Prior art keywords
- phenyl
- pyrazin
- amino
- trifluoromethyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261600324P | 2012-02-17 | 2012-02-17 | |
| US61/600,324 | 2012-02-17 | ||
| PCT/IB2013/051235 WO2013121387A1 (en) | 2012-02-17 | 2013-02-15 | Anti -malarial agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2864483A1 true CA2864483A1 (en) | 2013-08-22 |
Family
ID=48014134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2864483A Abandoned CA2864483A1 (en) | 2012-02-17 | 2013-02-15 | Aminopyrazine derivatives useful for the treatment or prevention of malaria |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9266842B2 (enExample) |
| EP (1) | EP2814820B1 (enExample) |
| JP (1) | JP6226889B2 (enExample) |
| CN (1) | CN104136426B (enExample) |
| BR (1) | BR112014020212B1 (enExample) |
| CA (1) | CA2864483A1 (enExample) |
| CY (1) | CY1118074T1 (enExample) |
| DK (1) | DK2814820T3 (enExample) |
| ES (1) | ES2589283T3 (enExample) |
| HR (1) | HRP20161237T1 (enExample) |
| HU (1) | HUE029876T2 (enExample) |
| IN (1) | IN2014MN01622A (enExample) |
| LT (1) | LT2814820T (enExample) |
| ME (1) | ME02535B (enExample) |
| PL (1) | PL2814820T3 (enExample) |
| PT (1) | PT2814820T (enExample) |
| SI (1) | SI2814820T1 (enExample) |
| SM (1) | SMT201600441B (enExample) |
| WO (1) | WO2013121387A1 (enExample) |
| ZA (1) | ZA201406786B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2589283T3 (es) * | 2012-02-17 | 2016-11-11 | University Of Cape Town | Agentes anti-malaria |
| EP3118198A1 (en) | 2015-07-13 | 2017-01-18 | MMV Medicines for Malaria Venture | Anti-malarial agents |
| WO2017067881A1 (en) | 2015-10-19 | 2017-04-27 | Glaxosmithkline Intellectual Property Development Limited | Pyrazine compounds for use in the treatment of parasitic protozoal infections |
| JP7057427B2 (ja) * | 2018-01-24 | 2022-04-19 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 寄生虫感染の処置のための新規化合物 |
| CN112142715A (zh) * | 2020-10-10 | 2020-12-29 | 鲁南制药集团股份有限公司 | 一种2-氨基-5-杂环基取代的吡嗪衍生物及其用途 |
| WO2023094305A1 (en) * | 2021-11-23 | 2023-06-01 | Glaxosmithkline Intellectual Property Development Limited | Pyrazine compounds useful in the treatment of parasitic protozoal infection |
| WO2024033280A1 (en) | 2022-08-09 | 2024-02-15 | Merck Patent Gmbh | Furopyridin and furopyrimidin, inhibitors of pi4k, for use in the treatment of parasite infection and malaria |
| CA3264304A1 (en) | 2022-08-09 | 2024-02-15 | Merck Patent Gmbh | FURO-PYRIMIDINE DERIVATIVES |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004294354B2 (en) * | 2003-12-03 | 2009-02-19 | Ym Biosciences Australia Pty Ltd | Tubulin inhibitors |
| EP2044051B1 (en) * | 2006-06-22 | 2010-01-27 | BIOVITRUM AB (publ) | Pyridine and pyrazine derivatives as mnk kinase inhibitors |
| EP1900727A1 (en) * | 2006-08-30 | 2008-03-19 | Cellzome Ag | Aminopyridine derivatives as kinase inhibitors |
| GB0625659D0 (en) | 2006-12-21 | 2007-01-31 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| PL2526090T3 (pl) * | 2010-01-18 | 2016-04-29 | Medicines For Malaria Venture Mmv | Nowe środki przeciwmalaryczne |
| EP2569286B1 (en) * | 2010-05-12 | 2014-08-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| KR20140014205A (ko) * | 2011-03-04 | 2014-02-05 | 렉시컨 파마슈티컬스 인코퍼레이티드 | Mst1 키나제 억제제 및 그의 사용 방법 |
| ES2589283T3 (es) * | 2012-02-17 | 2016-11-11 | University Of Cape Town | Agentes anti-malaria |
-
2013
- 2013-02-15 ES ES13712926.8T patent/ES2589283T3/es active Active
- 2013-02-15 ME MEP-2016-214A patent/ME02535B/me unknown
- 2013-02-15 EP EP13712926.8A patent/EP2814820B1/en active Active
- 2013-02-15 LT LTEP13712926.8T patent/LT2814820T/lt unknown
- 2013-02-15 US US14/379,332 patent/US9266842B2/en not_active Expired - Fee Related
- 2013-02-15 HU HUE13712926A patent/HUE029876T2/en unknown
- 2013-02-15 IN IN1622MUN2014 patent/IN2014MN01622A/en unknown
- 2013-02-15 CN CN201380009373.9A patent/CN104136426B/zh not_active Expired - Fee Related
- 2013-02-15 PT PT137129268T patent/PT2814820T/pt unknown
- 2013-02-15 SI SI201330290A patent/SI2814820T1/sl unknown
- 2013-02-15 JP JP2014557157A patent/JP6226889B2/ja not_active Expired - Fee Related
- 2013-02-15 HR HRP20161237TT patent/HRP20161237T1/hr unknown
- 2013-02-15 CA CA2864483A patent/CA2864483A1/en not_active Abandoned
- 2013-02-15 DK DK13712926.8T patent/DK2814820T3/en active
- 2013-02-15 WO PCT/IB2013/051235 patent/WO2013121387A1/en not_active Ceased
- 2013-02-15 PL PL13712926T patent/PL2814820T3/pl unknown
- 2013-02-15 BR BR112014020212-5A patent/BR112014020212B1/pt not_active IP Right Cessation
-
2014
- 2014-09-16 ZA ZA2014/06786A patent/ZA201406786B/en unknown
-
2016
- 2016-10-10 CY CY20161100998T patent/CY1118074T1/el unknown
- 2016-12-02 SM SM201600441T patent/SMT201600441B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015507004A (ja) | 2015-03-05 |
| CN104136426A (zh) | 2014-11-05 |
| HK1202859A1 (en) | 2015-10-09 |
| US20150031682A1 (en) | 2015-01-29 |
| ME02535B (me) | 2017-02-20 |
| SMT201600441B (it) | 2017-01-10 |
| BR112014020212B1 (pt) | 2021-11-23 |
| JP6226889B2 (ja) | 2017-11-08 |
| ZA201406786B (en) | 2015-06-24 |
| EP2814820A1 (en) | 2014-12-24 |
| SI2814820T1 (sl) | 2016-10-28 |
| US9266842B2 (en) | 2016-02-23 |
| LT2814820T (lt) | 2016-10-25 |
| IN2014MN01622A (enExample) | 2015-05-15 |
| CN104136426B (zh) | 2017-10-03 |
| ES2589283T3 (es) | 2016-11-11 |
| HRP20161237T1 (hr) | 2016-11-04 |
| HUE029876T2 (en) | 2017-04-28 |
| BR112014020212A8 (pt) | 2018-01-23 |
| EP2814820B1 (en) | 2016-07-20 |
| CY1118074T1 (el) | 2017-06-28 |
| PT2814820T (pt) | 2016-10-25 |
| WO2013121387A1 (en) | 2013-08-22 |
| DK2814820T3 (en) | 2016-10-03 |
| PL2814820T3 (pl) | 2017-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7767492B2 (ja) | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 | |
| DK2814820T3 (en) | Anti-malarials | |
| DK2526090T3 (en) | New antimalarials | |
| CN118063442A (zh) | 毒蕈碱性乙酰胆碱受体m4的拮抗剂 | |
| CN104352492A (zh) | 以芳基磺酰基衍生物作为有效成分的长链脂肪酸延长酶抑制剂 | |
| WO2024146632A1 (zh) | 一种四氢噻吩衍生物及其在医药上的应用 | |
| JP2022553284A (ja) | Ｔｒｅｋ（ｔｗｉｋ関連ｋ＋チャネル）チャネル機能の阻害剤 | |
| RS55998B1 (sr) | Novi anti-malarijski agensi | |
| JP2025522816A (ja) | 選択的ヒストンデアセチラーゼ８（ｈｄａｃ８）ディグレーダおよびその使用方法 | |
| EP4373485A1 (en) | Cxcr4 modulators and uses related thereto | |
| HK1202859B (en) | Anti -malarial agents | |
| WO2021123266A1 (en) | Anti-malarial agents | |
| KR20260025059A (ko) | 신규한 치환된 피리딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물 | |
| HK40112174A (zh) | 毒蕈硷性乙酰胆硷受体m4的拮抗剂 | |
| WO2025098417A1 (zh) | 磺酰胺类化合物及其应用 | |
| JP2026021396A (ja) | 新規の抗マラリア薬 | |
| HK40096710A (zh) | 用於治疗红细胞障碍和炎性疾病的四氢异喹啉衍生物 | |
| HK40119559A (zh) | 用於治疗与lpa受体活性相关的病症的化合物和组合物 | |
| RS55201B1 (sr) | Antimalarijski agensi | |
| HK1175472B (en) | New anti-malarial agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180202 |
|
| FZDE | Discontinued |
Effective date: 20221115 |
|
| FZDE | Discontinued |
Effective date: 20221115 |